LACTOLOGY FOUNDATION

Medicinal products in ATC class A06AG01 (sodium phosphate enemas) are considered compatible with breastfeeding; single or short-course rectal use does not usually require interruption of lactation, but they should be avoided or used with great caution in mothers with renal, cardiac or severe gastrointestinal disease.medpedia.framar+5

Pharmacological group overview

ATC A06AG01 comprises rectal saline laxatives containing sodium phosphate, indicated for the relief of occasional constipation and for bowel cleansing before lower bowel surgery, endoscopy or radiological examinations. Sodium phosphates act osmotically in the colonic lumen, drawing water into the intestinal contents, increasing stool volume, stimulating mechanoreceptors and enhancing colonic peristalsis to facilitate defecation. These preparations are generally supplied as prefilled single-use enemas of varying volumes for adults and paediatric patients, with rapid onset of action (defecation typically within 1–5 minutes).mohpublic.core.windows+3

Maternal pharmacokinetics and toxicity

When administered rectally as recommended, sodium phosphate is minimally absorbed systemically in healthy individuals with normal bowel motility and renal function. However, under conditions of bowel obstruction, megacolon, mucosal damage or retention of the enema solution, significant absorption of sodium and phosphate can occur, leading to electrolyte disturbances including hyperphosphataemia, hypernatraemia, hypocalcaemia and hypokalaemia, with potential clinical consequences such as tetany, dehydration, hypovolaemia, renal impairment and metabolic acidosis. Serious and even fatal outcomes have been reported after excessive dosing, repeated administration, or use in patients with obstructive gastrointestinal diseases or severe comorbidities, particularly in children and frail adults.ncbi.nlm.nih+6

Because sodium phosphate enemas can cause acute fluid shifts, they are contraindicated in patients with clinically significant renal impairment, congestive heart failure, dehydration, congenital or acquired megacolon, Hirschsprung’s disease, suspected intestinal obstruction, anorectal stenosis, imperforate anus, undiagnosed rectal bleeding and active inflammatory bowel disease. Concomitant use with other oral sodium phosphate preparations is discouraged due to cumulative risk of phosphate loading, and repeated or prolonged use beyond a few days can lead to dependence and chronic disturbances in mineral metabolism, including osteomalacia and bone pain.medlineplus+4

Lactation and effects on the breastfed infant

Phosphate is a normal physiological constituent of human breast milk, and maternal dietary phosphate intake contributes to this baseline level. Lactation-specific data and expert reviews indicate that oral or rectal phosphate-based laxatives, when used once or intermittently, result in negligible increases in maternal serum phosphate and do not meaningfully alter breast milk composition in mothers with normal renal function. LactMed explicitly states that phosphate rectal enemas used by nursing mothers require no special precautions and that it is generally unnecessary to suspend breastfeeding after one or two doses of sodium phosphate used for bowel evacuation. Similarly, independent lactation safety assessments classify dibasic sodium phosphate and related phosphate laxatives as compatible with breastfeeding and not risky for the breastfed infant.sps+4

Given the minimal systemic absorption and short duration of use at recommended doses, no adverse effects on full-term, healthy breastfed infants have been documented in association with maternal use of single-dose sodium phosphate enemas. Routine “pump and dump” strategies are therefore not indicated, and breastfeeding can continue as normal during and after treatment, provided the mother does not develop clinically significant toxicity.e-lactation+3

Clinical use in breastfeeding women

In breastfeeding women, sodium phosphate enemas may be used for short-term relief of occasional constipation or for bowel cleansing before lower gastrointestinal procedures, with preference for the lowest effective dose and avoidance of repeated daily administration over more than a few days. Because many laxatives are either not absorbed or minimally absorbed from the gastrointestinal tract, professional guidance generally considers any standard laxative acceptable in lactating women, and sodium phosphate enemas fall within this low-risk category when used appropriately. Nevertheless, breastfeeding patients should be screened for contraindications such as renal impairment, heart failure, dehydration, pre-existing electrolyte imbalance or conditions causing retention of the enema solution, and in such cases alternative laxatives (e.g. macrogol, lactulose) may offer a safer profile.ndi.fda.moph+8

Monitoring of maternal hydration status, blood pressure and, where clinically indicated, serum electrolytes is advisable in women with comorbidities or when more than one dose is used within 24 hours. If symptoms suggestive of electrolyte disturbance (e.g. muscle cramps, tetany, confusion, decreased urine output, severe weakness) arise after sodium phosphate enema administration, both the enema therapy and breastfeeding should be reassessed, and appropriate medical evaluation should be undertaken; however, in typical uncomplicated use these events are rare.ncbi.nlm.nih+5

Monograph summary table